Bioscibex: The Venture Leader Biotech leading accessible biomanufacturing

Meet Chloé Albietz, CEO of Bioscibex. The biotech company develops a single-use bioreactor-incubator that simplifies and automates cell culture, enabling faster, cheaper, and safer monoclonal antibody production. Chloé and the other nine Swiss National Biotech Team members will fly to Boston in June.

Name: Chloé Albietz
Location: Monthey, Switzerland
Nationality: French
Graduated from: EPFL (chemical engineering & biotechnology)
Prior role: Product manager at Procter & Gamble
Founding team members: Chloé Albietz (CEO), François Carruzzo (CTO)
Number of employees: 5
Money raised: CHF 2M (dilutive and non-dilutive)



What does your product or solution do, and what makes it unique?
Imagine developing a life-saving biologic drug, only to realize that millions of patients may never access it because manufacturing is too complex and the drug too expensive. This is the challenge of monoclonal antibodies, a USD 300B market. These therapies rely on living cells, and the industrial manufacturing process is still highly manual, requires multiple devices, and carries significant contamination risk. SW1NGO is a single-use bioreactor incubator that enables cell culture in 1 go: 1 device, 1 consumable, fully automated. With SW1NGO, we have demonstrated up to 50% cost reduction at global biopharma companies while maintaining the same product quality. 

What trend or shift in your industry is currently creating the biggest opportunity for you?
The monoclonal antibody market is expanding rapidly, valued at approximately USD 300 billion today and projected to reach USD 600 billion by 2030. This growth is being driven by the rising prevalence of chronic diseases such as cancer, the increasing presence of biosimilars, and more decentralized supply strategies. As demand grows, so does competition, particularly from countries such as China and India. To remain competitive, biopharmaceutical manufacturers must reduce their manufacturing costs.

How did the idea for your startup originate?
François Carruzzo, our CTO, invented SW1NGO to address a challenge he encountered while working in the biopharmaceutical industry at several companies (Merck, KBI Biopharma, and UCB). For more information, please watch our video.

Which market are you addressing, and what potential do you see for your startup in that market?
We address the biologics manufacturing market, specifically biopharma and CDMO companies. Our initial target is the cell culture and seed train segment, where SW1NGO solves a major operational bottleneck. Based on this focus, we estimate our total addressable market (TAM) at around USD 1 billion.

What major challenges have you faced so far?
One of our main challenges has been navigating the long qualification and sales cycles typical of the biopharma industry. However, we know that once customers complete their evaluation and decide to adopt SW1NGO, the commitment is significant: they do not purchase just one unit but deploy multiple systems as part of their manufacturing operations. This leads to deep integration within their manufacturing workflow, strong customer commitment, and the prospect of predictable, recurring revenues over the long term.

What motivates you on tough days?
Seeing customers smile when they realize how much simpler their work could become with SW1NGO. 

Why did you decide to join the Venture Leaders Roadshow, and what are you most excited about?
It is a unique opportunity to accelerate our U.S. expansion and prepare the company for its next stage of growth. In particular, we want to sharpen our U.S. market entry roadmap and strengthen our fundraising readiness ahead of our H2 2026 seed round. What excites us most is the opportunity to be in Boston, at the heart of one of the world’s leading biotech ecosystems, and to connect directly with investors, entrepreneurs, and industry leaders who can help accelerate our growth.